Your browser doesn't support javascript.
loading
First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers.
Fox, Jonathan C; Hellawell, Jennifer L; Rao, Satish; O'Reilly, Terry; Lumpkin, Rick; Jernelius, Jesper; Gretler, Daniel; Sinha, Uma.
Afiliação
  • Fox JC; Eidos Therapeutics, Inc., San Francisco, CA, USA.
  • Hellawell JL; Eidos Therapeutics, Inc., San Francisco, CA, USA.
  • Rao S; Eidos Therapeutics, Inc., San Francisco, CA, USA.
  • O'Reilly T; Celerion, Inc., Tempe, AZ, USA.
  • Lumpkin R; Eidos Therapeutics, Inc., San Francisco, CA, USA.
  • Jernelius J; Eidos Therapeutics, Inc., San Francisco, CA, USA.
  • Gretler D; Eidos Therapeutics, Inc., San Francisco, CA, USA.
  • Sinha U; Eidos Therapeutics, Inc., San Francisco, CA, USA.
Clin Pharmacol Drug Dev ; 9(1): 115-129, 2020 01.
Article em En | MEDLINE | ID: mdl-31172685
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Benzoatos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Benzoatos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article